Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Journal for immunotherapy of cancer·2026

Same author

Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia.

Transplantation and cellular therapy·2026

Same author

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.

Blood advances·2026

Same author

CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study.

Cancer research communications·2026

Same author

Outpatient Versus Inpatient Axicabtagene Ciloleucel CAR T-Cell Therapy in Non-Hodgkin's Lymphoma: Insights From A US Multicenter Transplant and Cellular Therapy Network.

Transplantation and cellular therapy·2026

Same author

Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.

Blood·2026

Search research articles

Related Experiment Video

Updated: Jun 7, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring.

Navneet S Majhail^1,2, Tonya Cox¹, Stephanie Larson¹

¹Sarah Cannon Transplant and Cellular Therapy Network, Sarah Cannon Cancer Network, Nashville, TN.

JCO Oncology Practice

|April 18, 2025

Summary

Outpatient administration of chimeric antigen receptor T-cell (CAR-T) therapies is safe and feasible. Remote patient monitoring and multidisciplinary teams are key to successful outpatient CAR-T programs, improving patient access and quality of life.

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Related Experiment Videos

Last Updated: Jun 7, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Area of Science:

Oncology
Immunotherapy
Hematology

Background:

Chimeric antigen receptor T-cell (CAR-T) therapy is a standard treatment for hematologic malignancies.
Hospitalization is common due to risks of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

Purpose of the Study:

To review models of care for outpatient CAR-T administration.
To provide operational considerations for establishing outpatient CAR-T programs.
To emphasize the role of remote patient monitoring (RPM) in facilitating outpatient care.

Main Methods:

Review of existing care models for outpatient CAR-T therapy.
Identification of operational considerations for program development.
Emphasis on the integration of remote patient monitoring (RPM).

Main Results:

Outpatient CAR-T administration is increasingly supported by evidence.
Multidisciplinary teams and clinical pathways are crucial for managing CRS and ICANS.
RPM can enable cost-effective scaling of outpatient programs and reduce acute care stays.

Conclusions:

Safe and high-quality outpatient CAR-T care is achievable with proper infrastructure.
Outpatient approaches can alleviate hospital capacity challenges and improve access to CAR-T therapy.
Minimizing hospitalizations enhances patient and caregiver experience and quality of life.